ArticleVeterinary medicine and science2025
Innovative Chitosan-Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative Chitosan-Based Formulation for Controlled Release of Enrofloxacin: Pharmacokinetic Analysis in Rabbits.Veterinary medicine and science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was conducted to evaluate the pharmacokinetics (PK) of a novel triple-layer formulation of enrofloxacin (ENR) compared to a conventional ENR formulation following subcutaneous (SC) administration in rabbits as an animal model. The triple-layer formulation comprised chitosan and β-glycerophosphate (β-GP) and was cross-linked with glutaraldehyde. The PK of the conventional ENR formulation was assessed after SC administration at a dosage of 10 mg/kg in rabbits; these results were subsequently compared with the disposition kinetics of the ENR film formulation. High-performance liquid chromatography (HPLC) was employed to quantify ENR concentrations in plasma, and non-compartmental analysis was utilized to calculate the PK parameters. The results indicated that the film formulation facilitated sustained drug release. The mean residence time (MRT) for ENR with the film formulation (F1) was significantly enhanced, presenting a 29-fold increase compared to the conventional formulation (p < 0.05). Although the C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.